Literature DB >> 12612980

B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.

Peter A McCullough1, Philippe Duc, Torbjørn Omland, James McCord, Richard M Nowak, Judd E Hollander, Howard C Herrmann, Philippe G Steg, Arne Westheim, Cathrine Wold Knudsen, Alan B Storrow, William T Abraham, Sumant Lamba, Alan H B Wu, Alberto Perez, Paul Clopton, Padma Krishnaswamy, Radmila Kazanegra, Alan S Maisel.   

Abstract

BACKGROUND: Both B-type natriuretic peptide (BNP) and renal function are prognostic indicators of survival in patients with congestive heart failure (CHF). However, relationships between BNP, renal function, and heart failure as an emergency diagnosis are unknown.
METHODS: The Breathing Not Properly Multinational Study was a prospectively designed diagnostic test evaluation study conducted in seven centers. Of 1,586 participants who presented with acute dyspnea, 1,452 patients (91.6%) had both BNP level and baseline estimated glomerular filtration rate (eGFR) available. Patients with an eGFR less than 15 mL/min/1.73 m2 and those on dialysis therapy were excluded. The final diagnosis was adjudicated by two independent cardiologists who were blinded to BNP results.
RESULTS: The final diagnosis was CHF in 715 patients (49.2%). Raw and log-log transformed correlations between BNP and eGFR values were r = -0.19 and r = -0.17 for those with CHF and r = -0.20 and r = -0.31 for those without CHF (both P < 0.0001 for r not equal 0). Mean BNP levels were 561.6 pg/mL (162.3 fmol/mL), 647.5 pg/mL (187.1 fmol/mL), 745.6 pg/mL (215.5 fmol/mL), and 850.7 pg/mL (245.8 fmol/mL) for those with CHF and 85.4 pg/mL (24.7 fmol/mL), 131.7 pg/mL (38.1 fmol/mL), 297.2 pg/mL (85.9 fmol/mL), and 285.0 pg/mL (82.3 fmol/mL) for those without CHF in eGFR categories of 90 or greater, 89 to 60, 59 to 30, and less than 30 mL/min/1.73 m2, respectively. The area under the receiver operating characteristic curve and optimum cut points for BNP were 0.91 and 70.7 pg/mL (20.4 fmol/mL), 0.90 and 104.3 pg/mL (30.1 fmol/mL), 0.81 and 201.2 pg/mL (58.1 fmol/mL), and 0.86 and 225.0 pg/mL (65.0 fmol/mL) for the eGFR categories of 90 or greater, 89 to 60, 59 to 30, and less than 30 mL/min/1.73 m2, respectively.
CONCLUSION: Renal function correlates weakly with BNP and influences the optimal cut point for BNP, particularly in those with an eGFR less than 60 mL/min/1.73 m2. Copyright 2003 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612980     DOI: 10.1053/ajkd.2003.50118

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  92 in total

1.  N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction.

Authors:  Justin A Ezekowitz; Pierre Théroux; Weiching Chang; Kenneth W Mahaffey; Christopher B Granger; W D Weaver; Judith S Hochman; Paul W Armstrong
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

2.  B-type natriuretic peptides for prediction and diagnosis of weaning failure from cardiac origin.

Authors:  Lluís Zapata; Paula Vera; Antoni Roglan; Ignasi Gich; Jordi Ordonez-Llanos; Antoni J Betbesé
Journal:  Intensive Care Med       Date:  2010-12-09       Impact factor: 17.440

Review 3.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

4.  B-type natriuretic peptide and weaning from mechanical ventilation.

Authors:  Armand Mekontso-Dessap; Nicolas de Prost; Emmanuelle Girou; François Braconnier; François Lemaire; Christian Brun-Buisson; Laurent Brochard
Journal:  Intensive Care Med       Date:  2006-08-29       Impact factor: 17.440

Review 5.  Natriuretic peptides in the diagnosis and management of heart failure.

Authors:  G Michael Felker; John W Petersen; Daniel B Mark
Journal:  CMAJ       Date:  2006-09-12       Impact factor: 8.262

6.  Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.

Authors:  Pedro J Flores-Blanco; Sergio Manzano-Fernández; Juan I Pérez-Calvo; Francisco J Pastor-Pérez; Francisco J Ruiz-Ruiz; Francisco J Carrasco-Sánchez; José L Morales-Rull; Domingo Pascual-Figal; Luis Galisteo-Almeda; James L Januzzi
Journal:  Clin Cardiol       Date:  2015-02-06       Impact factor: 2.882

Review 7.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

8.  Are levels of NT-proBNP and SDMA useful to determine diastolic dysfunction in chronic kidney disease and renal transplant patients?

Authors:  Lidija Memon; Vesna Spasojevic-Kalimanovska; Natasa Bogavac Stanojevic; Jelena Kotur-Stevuljevic; Sanja Simic-Ogrizovic; Vojislav Giga; Violeta Dopsaj; Zorana Jelic-Ivanovic; Slavica Spasic
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

Review 9.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

10.  [Essential cardiac biomarkers in myocardial infarction and heart failure].

Authors:  M Mueller; E Giannitsis; H A Katus
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.